He Liu: The Shift in China’s Medtech Sector is Truly a Game-Changer
He Liu, Chief Executive Officer at IMPELINNO GmbH, reposted from China Medtech Radar on LinkedIn:
”The shift in China’s Medtech sector is truly a game-changer, and our latest intelligence report, “The Surgeon-Engineered Solution,” captures the pivot point.
We are witnessing a fundamental move from being a cost-driven “Manufacturing” hub to a high-value “Intelligent Manufacturing” powerhouse, driven by the Med-Eng Integration model.
This means Chinese urgeons are now the primary nnovators, using their deep clinical insights to architect superior, clinical-driven devices like the ValveClamp® for TEER, MissilEX® thrombectomy and beyond, which exemplify the competitive landscape in China’s Medtech Innovation ecosystem.
I invite you to read the full analysis and engage with us: How can we best collaborate to plug into this high-velocity ecosystem? Let’s drive the future of MedTech together.”
Quoting China Medtech Radar‘s post:
”China’s medtech innovation model is undergoing a seismic shift!
The evolution of China’s medtech innovation from a cost-driven model to a clinical-led ecosystem warrants strategic consideration from the global medtech community.
We are excited to share our latest intelligence report, “The Surgeon-Engineered Solution,” which provides unique insight into the driving force behind China’s move from “Manufacturing” to “Intelligent Manufacturing.”
Key Takeaways for Global Stakeholders:
- The Surgeon as the Innovator: Chinese physicians are no longer just users; they are the source of medtech innovation. Their deep, clinical insights into unmet clinical needs are defining product development from the ground up, creating “China Solutions” to real-world problems.
- Med-Eng Integration: This is a highly efficient “Clinical-Engineering-Industry-Policy” ecosystem. It means surgeons and engineers collaborate from Day One to solve clinical pain points, leading to rapid RandD and shorter time-to-market.
- From Manufacturing to IntelligentManufacturing: This is the shift from a cost-focused, often imitative production model to a high-value, data-driven system utilizing AI and robotics to achieve breakthroughs in precision and quality.
- Real-World Success: Learn how this model has led to breakthroughs in China’s medtech like the Valve Clamp, Mitral Clip System (democratizing advanced repair), the MissilEX Intracranial Thrombectomy Device (demonstrating superior first-pass recanalization rates) and the Orthopedic Surgical Robot.
The competitive landscape in China’s medtch is being redefined.
For global medtech stakeholders, understanding this clinically-driven model is critical for successful internationalcollaboration and marketstrategy.
We invite you to read our exclusive analysis and join the conversation on fostering a collaborative future for medtechinnovation between China and the world.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI
-
Sep 5, 2026, 11:39Julie Rayes: Sepsis Rewrites the Role of Mast Cells in Thrombosis
-
Sep 5, 2026, 11:30Shirley D’Sa: Chemoimmunotherapy in Cold Agglutinin Disease and WM-Associated CAS
-
Sep 5, 2026, 11:29Dilini Christina Ranasinghe: An Exception to the ‘Universal Donor’ – Bombay (Oh)
-
Sep 5, 2026, 11:10Amanda Stahl: Integrating Psychosocial Care Into Comprehensive Hemophilia Treatment
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera